Vineet Laboratories Limited
Vineet Laboratories Limited (VINEETLAB) financial statements and selected valuation metrics from NSE/BSE exchange filings through 31 December 2025.
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
vineetlabs.co.in(opens the company website in a new tab)Key metrics
Price as of 2026-09-02
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Mar 2025 | Jun 2025 | Sept 2025 |
|---|---|---|---|
| Sales | 14 Cr | 7 Cr | 17 Cr |
| Operating expenses (approx.) | 25 Cr | 7 Cr | 14 Cr |
| EBITDA | -11 Cr | 0.32 Cr | 3 Cr |
| OPM % | -78.5% | 4.3% | 18.2% |
| Other income | 1 Cr | 0.02 Cr | 0.0084 Cr |
| Interest | 0.90 Cr | 0.61 Cr | 2 Cr |
| Depreciation | 0.66 Cr | 0.63 Cr | 0.63 Cr |
| Profit before tax | -11 Cr | -0.90 Cr | 0.37 Cr |
| Tax % | 6.2% | 3.9% | -7.9% |
| Net profit | -11 Cr | -0.87 Cr | 0.40 Cr |
| EPS (₹) | ₹-11.42 | ₹-0.94 | ₹0.43 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2025 | TTM |
|---|---|---|
| Sales | 75 Cr | Sign in for TTM |
| Operating expenses (approx.) | 91 Cr | Sign in for TTM |
| EBITDA | -16 Cr | Sign in for TTM |
| OPM % | -21.7% | Sign in for TTM |
| Other income | 2 Cr | Sign in for TTM |
| Interest | 4 Cr | Sign in for TTM |
| Depreciation | 3 Cr | Sign in for TTM |
| Profit before tax | -21 Cr | Sign in for TTM |
| Tax % | 2.8% | Sign in for TTM |
| Net profit | -20 Cr | Sign in for TTM |
| EPS (₹) | ₹-21.90 | Sign in for TTM |
| Dividend payout % | — | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2025 |
|---|---|
| Equity capital | 9 Cr |
| Reserves | 5 Cr |
| Borrowings | 40 Cr |
| Other liabilities | 40 Cr |
| Total liabilities | 95 Cr |
| Fixed assets (net) | 25 Cr |
| CWIP | — |
| Investments | 0.21 Cr |
| Inventories | 50 Cr |
| Trade receivables | 13 Cr |
| Cash & bank | 0.31 Cr |
| Other assets | 5 Cr |
| Total assets | 95 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2025 |
|---|---|
| Cash from operating activity | 11 Cr |
| Cash from investing | -3 Cr |
| Cash from financing | -8 Cr |
| Net cash flow | 0.08 Cr |
| Free cash flow (OCF − Capex) | 10 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2025 |
|---|---|
| ROCE % | -30.7% |
| ROE % | -137.8% |
| Debtor days | 64 |
| Inventory days | 285 |
| Days payable | 192 |
| Cash conversion cycle | 158 |
| Debt / equity | 2.73 |
| Current ratio | 0.91 |
| Net debt / EBITDA | — |
Compare with peers
Loading peers…